Arc: a therapeutic hub for Alzheimer's disease.
VanDongen, A. M.
Show abstract
Alzheimers disease (AD) is poised to reach epidemic levels as the world population ages. There is currently no treatment that halts this debilitating disease. Our recent finding that the memory gene Arc regulates the expression of many genes associated with the pathophysiology of AD sets the stage for a new therapeutic approach that is not structurally based on the amyloid hypothesis that has driven most research to date. Neuronal activity-dependent Arc expression is controlled by a chromatin-modification complex containing two enzymes: Tip60 and PHF8. Here, we show that small molecules targeting these proteins inhibit Arc expression. This finding sets the stage for a novel therapeutic approach to combat Alzheimers disease. Targeting Arc opens a new frontier of "multi-target" therapy designed to intervene in several aspects of the disease simultaneously. Because of Arcs role in controlling the expression of multiple genes and pathways implicated in AD, it could serve as a therapeutic hub.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Arginase Inhibition Supports Survival and Differentiation of Neuronal Precursors in Adult Alzheimer's Disease Mice 94%
- Identification of a cardiac glycoside exhibiting favorable brain bioavailability and potency for reducing levels of the cellular prion protein 94%
- Small-molecule inhibitors of the RNA m6A demethylase FTO potently support the survival of dopamine neurons 94%
Similar papers in this journal
- Quantitative 3D histochemistry reveals region-specific amyloid-β reduction by the antidiabetic drug netoglitazone 94%
- Queuine, a bacterial derived hypermodified nucleobase, shows protection in in vitro models of neurodegeneration 94%
- Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological assessment of target engagement in a mouse model of Alzheimer's related amyloid-beta pathology 93%
Similar papers in this journal
- Exifone is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration 94%
- A subtle structural modification of a synthetic cannabinoid receptor agonist drastically increases its efficacy at the CB1 receptor 94%
- A patient-derived blood-brain barrier model for screening copper bis(thiosemicarbazone) complexes as potential therapeutics in Alzheimer's disease 93%
Similar papers in this journal
- Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology 96%
- A peptide-neurotensin conjugate that crosses the blood-brain barrier induces pharmacological hypothermia associated with anticonvulsant, neuroprotective and anti-inflammatory properties following status epilepticus in mice 94%
- Water-soluble 4-(dimethylaminomethyl)heliomycin exerts greater antitumor effects than parental heliomycin by targeting the tNOX-SIRT1 axis and apoptosis in oral cancer cells 93%
Similar papers in this journal
- Early astrocytic dysfunction is associated to mistuned synapses as well as anxiety and depressive-like behavior in the AppNL-F mouse model of Alzheimers disease 94%
- Association of GLOD4 with Alzheimers Disease in Humans and Mice 93%
- Transcriptional and translational regulation of pathogenesis in Alzheimer's disease model mice 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.